Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone

BMC Cancer

Research Article

Maurice Balke¹  Carsten Gebert¹  Pancras Hogendoorn²  Judith Kroep²  Laura Campanacci³  Piero Picci³  Max Gibbons⁴  John Wass⁴  Richard Taylor⁴  Nicholas Athanasou⁴ 

[1] Department of Orthopaedic Surgery, University of Munster, Albert-Schweitzer-Str. 3, 48149, Munster, Germany;Department of Pathology, Leiden University Medical Centre, P.O. Box 9600, L1-Q, Albinusdreef 2, Leiden, 2300, Leiden, RC, The Netherlands;Laboratory of Oncologic Research, Orthopaedic Institute Rizzoli, Via di Barbiano 1/10, 40136, Bologna, Italy;Nuffield Department of Orthopaedic Surgery, Department of Pathology, Nuffield Orthopaedic Centre, University of Oxford, OX3 7LD, Oxford, UK;

关键词: Alendronate;    Zoledronic Acid;    Denosumab;    Pamidronate;    Fibrous Dysplasia;   

DOI  :  10.1186/1471-2407-10-462

 received in 2010-01-22, accepted in 2010-08-29,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundGiant cell tumour of bone (GCTB) is an expansile osteolytic tumour which contains numerous osteoclast-like giant cells. GCTB frequently recurs and can produce metastatic lesions in the lungs. Bisphosphonates are anti-resorptive drugs which act mainly on osteoclasts.MethodIn this study, we have examined clinical and radiological outcomes of treatment with aminobisphosphonates on 25 cases of aggressive primary, recurrent and metastatic GCTB derived from four European centres. We also analysed in vitro the inhibitory effect of zoledronic acid on osteoclasts isolated from GCTBs.ResultsTreatment protocols differed with several different aminobisphosphonates being employed, but stabilisation of disease was achieved in most of these cases which were refractory to conventional treatment. Most inoperable sacral/pelvic tumours did not increase in size and no further recurrence was seen in GCTBs that had repeatedly recurred in bone and soft tissues. Lung metastases did not increase in size or number following treatment. Zoledronic acid markedly inhibited lacunar resorption by GCTB-derived osteoclasts in vitro.ConclusionOur findings suggest that bisphosphonates may be useful in controlling disease progression in GCTB and that these agents directly inhibit GCTB - derived osteoclast resorption. These studies highlight the need for the establishment of standardised protocols to assess the efficacy of bisphosphonate treatment of GCTB.

【 授权许可】

Unknown   
© Balke et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.